Navigation Links
Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment
Date:7/23/2008

under Section 505(b)(2)".

Dr. Amir Pelleg, Duska's President and Chief Scientific Officer, stated, "I expect that the Special Protocol Assessment by the FDA would facilitate the completion of the clinical development of ATPace(TM) in a timely fashion".

About ATPace(TM)

ATPace(TM) (adenosine triphosphate injection) is a proposed product for the termination of paroxysmal supraventricular tachycardia (PSVT). The bradycardic effect of ATP, in particular its blockade of atrio-ventricular nodal (AVN) conduction, has been shown to effectively terminate re-entrant PSVT involving the AV node. Adenosine is the only approved competition in the U.S. Duska believes that the initial dose of ATPace(TM) will be significantly more efficacious than the initial labeled dose of adenosine in terminating PSVT. While ATP and adenosine both inhibit AVN conduction, ATPace(TM) is believed to have a second mechanism of action to stimulate vagally-mediated suppression of AVN conduction. Injectable formulations of ATP have been approved in Europe for over 50 years as safe and efficacious treatments for PSVT. Duska has completed Phase 1 and 2 clinical trials in diagnosing bradycardia, and has acquired more than 1,000 patients records from other clinical trials. Duska has met with the FDA to ascertain which additional requirements might be necessary for marketing approval of ATPace(TM). Duska plans a 505(b)(2) NDA filing route for approval.

About Duska Therapeutics, Inc.

Duska Therapeutics, Inc. (Duska) is a specialty pharmaceutical company that develops new cardiovascular and pulmonary medicines based upon the emerging new pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which by several pharmaceuticals constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Duska is developing a portfolio of investi
'/>"/>

SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Duska Therapeutics Obtains Standard & Poors Listing
2. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
3. CV Therapeutics to Announce 2008 Second Quarter Financial Results on Thursday, July 31, 2008
4. Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008
5. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
6. Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
7. Organizational Changes at Silence Therapeutics
8. Genzyme Corporation and PTC Therapeutics Announce Collaboration on Small Molecule for Genetic Diseases
9. Arno Therapeutics Announces New Ticker Symbol
10. Lorus Therapeutics Receives $600 Thousand From Escrow Account
11. Silence Therapeutics Announces Successful Opposition of Glover Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... ... presented new data on the relationship of genetics and hypertension at the ... Heart Disease in Vancouver, British Columbia, Canada. The event, which boasts an extensive ...
(Date:8/26/2015)... 2015  The Diabetes Research Institute (DRI), a ... Miller School of Medicine, announced today that the ... for the first time a novel transplant technique ... approved Phase I/II study builds upon decades of ... important first step toward the development of the ...
(Date:8/26/2015)... After litigating and negotiating patent infringement ... P2i United States patent RE43,651 (the ... the United States without any admission or ... party. As a result of the parties, settlement, the US ... dismissed the case without prejudice. Under ...
(Date:8/25/2015)... and CARDIFF, UK (PRWEB) , ... August 25, ... ... and accurately determining whether breast tissue lesions are cancerous is described by University ... SPIE, the international society for optics and photonics. , In “ Breast cancer ...
Breaking Biology Technology:Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4P2i Settles United States Litigation 2New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 2New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 4
... ROCKVILLE, Md., Aug. 24 /PRNewswire / --OriGene Technologies, ... representing the most comprehensive offering of human cell-produced human ... are purified from HEK293 cells transiently transfected with TrueORF ... to other expression systems in that it produces proteins ...
... BOZEN, Italy, August 24 Health ... recent partnership announcement with McKesson, it,has received categorical ... American,customers in just a few days since the ... prevent them from publicly,commenting on industry events, a ...
... SAN DIEGO, Aug. 24 Orexigen((R)) Therapeutics, Inc. (Nasdaq: ... joined the Company as Chief Commercial Officer. Mr. Booth ... to Orexigen. Most recently he served as President of ... commercial, medical and scientific affairs, business development and all support ...
Cached Biology Technology:Health Robotics Receives Overwhelming Support from its Customers for its McKesson-CytoCare Partnership 2Health Robotics Receives Overwhelming Support from its Customers for its McKesson-CytoCare Partnership 3Health Robotics Receives Overwhelming Support from its Customers for its McKesson-CytoCare Partnership 4Orexigen(R) Therapeutics Appoints Mark Booth Chief Commercial Officer 2
(Date:8/4/2015)... ALBANY, N.Y., Aug. 4, 2015  AMRI (NASDAQ: AMRI ) ... June 30, 2015. Highlights: , Second quarter ... increase from 2014 , Adjusted contract margins of ... EPS of $0.22, including a $0.05 decrease in EPS from royalties ... of $16 million "We are very pleased to ...
(Date:7/31/2015)... 31 de julho de 2015 A 10 ... ) será realizada pela BGI de 22-25 de outubro de ... A conferência está celebrando seu 10 o. ... ICG se tornou uma das reuniões mais influentes do ... científicos mais dinâmicos, entusiastas e prazerosos. ...
(Date:7/31/2015)... Conn. , Jul. 31, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... that it has filed provisional patent 62/198989 for ... This invention highlights a method to advance crypto-currencies such ... by introducing a common, uniform way to manage all ...
Breaking Biology News(10 mins):AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
... pay attention in math class. Nature Communications ... how advanced mathematical modelling can be used in the ... and genetic modifications might allow cancer-killing, oncolytic viruses to ... stave off viral infection. "Oncolytic viruses are ...
... 2013)A new study shows that combining improved oyster restoration methods ... the oyster population back to the Bay in a much ... of the University of Maryland Center for Environmental Science,s Chesapeake ... to see which ones would have the most likelihood success. ...
... high risk for breast cancer, a long-term drug treatment can ... supported by the National Institutes of Health have now identified ... likely to benefit from this therapyand which should avoid it. ... individualized breast cancer prevention in women at high risk for ...
Cached Biology News:Using math to kill cancer cells 2Oysters could rebound more quickly with limited fishing and improved habitat 2Gene variants may predict who will benefit from breast cancer prevention drugs 2Gene variants may predict who will benefit from breast cancer prevention drugs 3
Human Cell Line Slides...
Human Cell Line Slides...
... Each Signet Level 2 Detection ... the avidin-biotin chemical bonding principle and ... to provide sensitivity, specificity and reliablility. ... immunostaining in both manual and automated ...
Mouse monoclonal [3576] to Yellow Fever Virus ( Abpromise for all tested applications). Antigen: Tissue / cell preparation...
Biology Products: